49,260
edits
(→IHC) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 92: | Line 92: | ||
===Sebaceous carcinoma versus squamous cell carcinoma=== | ===Sebaceous carcinoma versus squamous cell carcinoma=== | ||
*CK7 +ve. | *CK7 +ve. | ||
**Useful if positive: 24 of 27 sebaceous carcinomas +ve; only 2 of 22 squamous cell carcinomas | **Useful if positive: 24 of 27 sebaceous carcinomas +ve; only 2 of 22 squamous cell carcinomas +ve.<ref name=pmid26485238>{{cite journal |authors=Plaza JA, Mackinnon A, Carrillo L, Prieto VG, Sangueza M, Suster S |title=Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study |journal=Am J Dermatopathol |volume=37 |issue=11 |pages=809–21 |date=November 2015 |pmid=26485238 |doi=10.1097/DAD.0000000000000255 |url=}}</ref> | ||
*Ber-EP4 -ve/+ve. | *Ber-EP4 -ve/+ve. | ||
**Useful if positive: 7 of 27 sebaceous carcinomas +ve; 0 of 22 squamous cell carcinomas | **Useful if positive: 7 of 27 sebaceous carcinomas +ve; 0 of 22 squamous cell carcinomas +ve.<ref name=pmid26485238/> | ||
*EMA +ve. | *EMA +ve. | ||
**Useful if negative: 27 of 27 sebaceous carcinoma | **Useful if negative: 27 of 27 sebaceous carcinoma +ve; 16 of 22 squamous cell carcinoma +ve.<ref name=pmid26485238/> | ||
==Sign out== | ==Sign out== | ||
edits